A Novel Paclitaxel Microemulsion Containing a Reduced Amount of Cremophor EL: Pharmacokinetics, Biodistribution, and In Vivo Antitumor Efficacy and Safety
Figure 5
The mean tumor weight in the 5% glucose infusion, PTX injection and PTX microemulsion groups at day 33 after OVCAR-3 cell implantation (a) or A-549 cells (b) at day 32 after A 549 cell implantation. Results are given as means ± S.D. (). ** versus 5% glucose infusion as control.
